Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycaemia. SUs—which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide—stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.
A new systematic review of randomized clinical trials lasting 12 to 52 weeks found that when added to metformin, gliclazide confers the lowest risk of hypoglycaemia compared with glipizide, glimepiride, and glibenclamide.
“Risk of hypoglycaemia with the SU agents makes the newer and more expensive antidiabetics preferable when metformin monotherapy fails. However, our data indicate that the risk of hypoglycaemia differs between the SU agents,” said Dr. Stig Ejdrup Andersen, co-author of the British Journal of Clinical Pharmacology analysis. “Thus, prescribing an SU with low risk of hypoglycaemia might still be a rational and affordable alternative to many patients with type 2 diabetes.”
Access the full article.
